New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Citius Pharmaceuticals, Inc. (CTXR) vs Seres Therapeutics, Inc. (MCRB)
- Citius Pharmaceuticals, Inc. CTXR 0.51 +2.00%
- Seres Therapeutics, Inc. MCRB 1.24 −6.77%
Citius Pharmaceuticals, Inc. and Seres Therapeutics, Inc. are both Biotechnology companies. Citius Pharmaceuticals, Inc. and Seres Therapeutics, Inc. are of similar size ($13.7M and $13.6M). Citius Pharmaceuticals, Inc. has the higher net margin (0.00% vs −2,209.6%) and the higher return on invested capital (−58.7% vs −1,267.8%). Across the 11 metrics below, Citius Pharmaceuticals, Inc. leads on 8 and Seres Therapeutics, Inc. on 3.
Valuation
Profitability
| Metric | CTXR | MCRB | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 100.00% | 70.18% |
| Operating margin | 0.00% | (3,656.89%) | 0.00% |
| Net margin | 0.00% | (2,209.55%) | 0.00% |
| Free cash flow margin | 0.00% | — | 0.00% |
| Return on equity | (64.51%) | (144.35%) | (51.58%) |
| Return on assets | (34.29%) | (44.85%) | (45.91%) |
| Return on invested capital | (58.74%) | (1,267.77%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack